BBIO News and Press, BridgeBio Pharma Inc. From 10/28/25

PALO ALTO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced plans to release topline results of the autosomal dominant hy...

2025-10-28 10:15:19 ET H.C. Wainwright analyst issues BUY recommendation for BBIO on October 28, 2025 10:10AM ET. The previous analyst recommendation was Buy. BBIO was trading at $63.1788 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cu...

2025-10-27 13:09:28 ET More on BridgeBio Pharma BridgeBio Pharma, Inc. (BBIO) Discusses Positive FORTIFY Phase III Interim Results in Limb-Girdle Muscular Dystrophy Type 2I/R9 Transcript BridgeBio Pharma, Inc. (BBIO) Discusses Positive FORTIFY Phase III Interim Results in Li...

2025-10-27 11:17:51 ET BridgeBio Pharma, Inc. (BBIO) Discusses Positive FORTIFY Phase III Interim Results in Limb-Girdle Muscular Dystrophy Type 2I/R9 October 27, 2025 8:00 AM EDT... Read the full article on Seeking Alpha For further details see: BridgeBio Pharma, Inc. (BBIO...

- All primary and secondary interim analysis endpoints in FORTIFY Phase 3 study successfully achieved with well-tolerated safety profile consistent with the Company’s prior studies - Primary interim analysis endpoint, glycosylated αDG, significantly increased by 1.8x change ...

PALO ALTO, Calif., Oct. 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will host two separate bu...

2025-10-23 12:19:26 ET More on Bristol-Myers Squibb, Johnson & Johnson, etc. The Play On Bristol-Myers Squibb Merck: Earnings Outlook Steady, Keytruda Now Has Some Breathing Room Merck: A Golden Buying Opportunity Merck Keytruda formulations undergo FDA p...

2025-10-14 10:17:06 ET Shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO) traded at a new 52-week high today and are currently trading at $56.28. So far today, approximately 168.56k shares have been exchanged, as compared to an average 30-day volume of 1.78M shares. BridgeBio Pharma, I...

2025-10-12 15:37:29 ET More on BridgeBio Pharma, Immuneering BridgeBio Pharma, Inc. (BBIO) Presents at HFSA 2025 - Slideshow Immuneering Corporation (IMRX) Special Call - Slideshow Immuneering Corporation (IMRX) Discusses Phase 2a Data Update For IMM-1-104 In First-L...

- By Month 1, numerically fewer cumulative events were observed with acoramidis compared to placebo - Acoramidis significantly reduced the cumulative risk of CVM or recurrent CVH through Month 30 versus placebo with a 49% hazard reduction (p<0.0001) - The difference in cumu...